Back to search results

Observational Study for Older Adults with Liver Cancer

This study is looking at how liver cancer (hepatocellular carcinoma or HCC) affects older adults and how they respond to treatments. It's an observational study, meaning researchers will collect information about your disease and treatment without giving you a new medicine. They will use a Comprehensive Geriatric Assessment (CGA) for participants aged 65 and older to understand their overall health. The goal is to learn more about the disease and treatment patterns in older adults with advanced, unresectable HCC. This information could help doctors create better, more personalized treatment plans in the future. The study plans to include 84 participants and is currently collecting data.

Study design
This is an observational study that plans to enroll 84 participants. It will collect information over time rather than testing a specific treatment.
What's involved
You would have assessments at screening, and then at months 1, 2, 4, 6, 8, 10, and 12. For those 65 or older, a Comprehensive Geriatric Assessment will be done before standard treatment.
Compensation
Not stated in the trial record.
Follow-up
Observations will be collected for 12 months after screening.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03894917

Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma

Recruiting
Not specifiedAges 18+Observational
The University of Texas Health Science Center at San Antonio
~84 participants
Updated 2026-01-08 on ClinicalTrials.gov
What's tested:Comprehensive Geriatric Assessment (CGA)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Characterize the Change in disease and treatment patterns of advanced hepatocellular carcinoma (HCC) in older patients in the US.
Measured over will be collected at time points: at screening, Month 1, Month 2, Month 4, Month 6, Month 8, Month 10 and Month 12.

Conditions

Carcinoma, Hepatocellular

Explore related trials

Hepatocellular Carcinoma

NCT03894917

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Mays Cancer Center

    San Antonio, Texasstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Sukeshi Patel Arora, MD · PRINCIPAL_INVESTIGATOR · Mays Cancer Center

Who to contact

Maggie Tomasini, MPH
[email protected]
210-450-0507
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Histologically or radiographically (CT or MRI) confirmed newly diagnosed hepatocellular carcinoma.
Age 18 years and older.
Patients with advanced, unresectable HCC as determined by the treating physician.

Exclusion

Patients with resectable HCC who are still candidates for locoregional therapy
Patients receiving prior systemic or locoregional therapy

What this trial measures

  • Characterize the Change in disease and treatment patterns of advanced hepatocellular carcinoma (HCC) in older patients in the US.will be collected at time points: at screening, Month 1, Month 2, Month 4, Month 6, Month 8, Month 10 and Month 12.

    Collection of the participants disease characteristics, clinical and treatment data. Comprehensive geriatrics assessments will be done using bilingual assessments in English and Spanish.